Table 1.

Enzyme inhibitory and antiproliferative activities of the derived hydroxamic acid containing compounds.

Compounds	R1	HDACsa	U937b	U266b	HepG2b
I1	–H	53.81 ± 1.60	1.02 ± 0.13	0.84 ± 0.09	8.98 ± 0.16
I2		78.94 ± 3.41	0.95 ± 0.04	0.48 ± 0.09	3.63 ± 0.26
I3	–C2H5	78.94 ± 2.34	0.94 ± 0.04	0.24 ± 0.03	1.92 ± 0.05
I4		68.50 ± 1.22	0.97 ± 0.04	0.96 ± 0.08	4.45 ± 0.25
I5		19.30 ± 1.60	4.42 ± 0.18	0.88 ± 0.07	6.17 ± 0.21
I6		16.14 ± 1.07	1.25 ± 0.21	0.82 ± 0.06	7.72 ± 0.34
I7		46.17 ± 2.94	0.95 ± 0.01	0.84 ± 0.06	4.87 ± 0.12
I8		15.87 ± 3.27	1.94 ± 0.17	0.71 ± 0.06	6.45 ± 0.28
I9		56.68 ± 2.42	1.00 ± 0.15	0.65 ± 0.04	5.67 ± 0.06
I10		79.10 ± 4.65	0.63 ± 0.07	0.16 ± 0.07	3.39 ± 0.25
I11		52.24 ± 1.10	4.58 ± 0.23	0.74 ± 0.05	4.76 ± 0.61
I12	–(CH2)3CH3	62.70 ± 1.63	1.01 ± 0.03	0.12 ± 0.02	5.76 ± 0.65
I13	–CH3	82.19 ± 1.60	0.93 ± 0.08	0.16 ± 0.04	1.85 ± 0.31
SAHA		59.91 ± 3.73	1.40 ± 0.02	0.88 ± 0.08	8.68 ± 0.29

^a Percentage inhibition rate (%, at the concentration of 1 µM), HeLa nucleus extract was used for the test. Each value is the mean of at least three experiments.

^b IC₅₀, µM. Each value is the mean of at least three experiments.